Metagenomi Reports Q2 Cash of $120.7M, Runway Through Q4 2027; IND Filing on Track
MGX is trading near its 52-week low of $1.13 (6.2% above the low).
Summary
Metagenomi reported Q2 2026 financials with cash of $120.7M, down from $160.8M at year-end, and a cash runway through Q4 2027. R&D expenses were flat at $22.5M, while G&A dipped to $6.0M from $7.0M. The company remains on track to submit an IND for its hemophilia A gene-editing therapy MGX-001 in Q4 2026, with clinical trials expected in 2027. The Q2 net loss widened, and a 10-Q filing highlighted a negative revenue adjustment and accelerated cash burn. The steady R&D spend and reiterated timeline provide some reassurance, but the declining cash position and lack of near-term catalysts keep the outlook cautious.
At the time of this announcement, MGX was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.3M. The 52-week trading range was $1.13 to $3.95. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.